Highly Potent Active Pharmaceutical Ingredients
The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future
With over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimize risk and advanced manufacturing processes. In addition, the conference aims to guide attendees through novel regulatory updates for each stage of HPAPI development.
PCI’s Director of Scientific Affairs David O’Connell will be speaking at this event.
Date & Time
13 May 2019 - 14 May 2019 - All Day
Copthorne Tara Hotel
Scarsdale Place, Kensington